Revenue from Contract with Customer, Excluding Assessed Tax

Halozyme Therapeutics·Products & Services·9 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Royalties	$124.92M	$155.06M	$170.42M	$168.19M	$205.64M	$236.04M	$257.97M	$240.68M
Bulk rHuPH20 sales	$24.63M	$31.49M	$19.7M	$27.03M	$23.27M	$32.49M	$50.24M	$73.5M
Proprietary product sales	$44.14M	$39.93M	$47.3M	$36.34M	$46.45M	$52.24M	$59.57M	$41.87M
Device partnered product sales	$10.11M	$15.24M	$12.37M	$14.68M	$11.79M	$9.5M	$12.86M	$15.05M
Device licensing and development revenue	$2.05M	$3.36M	$3.23M	$3.41M	$4.07M	$4M	$5.38M	$5.6M
Upfront license and target nomination fees	$0	$27M	$0	$220K	$0	$0	$18.25M	$0
Sales-based milestones	$0	$0	$30M	$15M	$10M	$20M	$25M	$0
Total	$231.35M	$290.08M	$298.01M	$264.86M	$325.72M	$354.26M	$451.77M	$376.71M

Product sales, netView metric

Revenues under collaborative agreementsView metric

Proprietary product salesView metric

Bulk rHuPH20 salesView metric

Device partnered product salesView metric

Upfront license and target nomination feesView metric

Sales-based milestonesView metric

Device licensing and development revenueView metric